Identifying SARS-CoV-2 Drugs Binding to the Spike Fatty Acid Binding Pocket Using In Silico Docking and Molecular Dynamics
暂无分享,去创建一个
[1] Ashutosh Kumar Singh,et al. Discovery of anti-SARS-CoV-2 molecules using structure-assisted repurposing approach targeting N-protein , 2023, bioRxiv.
[2] Clara D. Christ,et al. Prioritizing Small Sets of Molecules for Synthesis through in‐silico Tools: A Comparison of Common Ranking Methods , 2022, ChemMedChem.
[3] C. Fernandez-Patron,et al. Could Endogenous Glucocorticoids Influence SARS-CoV-2 Infectivity? , 2022, Cells.
[4] Chengyu Jiang,et al. Potential of angiotensin II receptor blocker telmisartan in reducing mortality among hospitalized patients with COVID-19 compared with recommended drugs , 2022, Cell discovery.
[5] A. Barabasi,et al. Identification of potent inhibitors of SARS-CoV-2 infection by combined pharmacological evaluation and cellular network prioritization , 2022, iScience.
[6] N. Petrovsky,et al. Potential COVID-19 Therapies from Computational Repurposing of Drugs and Natural Products against the SARS-CoV-2 Helicase , 2022, International journal of molecular sciences.
[7] J. Glover,et al. Glucocorticoids Bind to SARS-CoV-2 S1 at Multiple Sites Causing Cooperative Inhibition of SARS-CoV-2 S1 Interaction With ACE2 , 2022, Frontiers in Immunology.
[8] Mateusz Kciuk,et al. Discovery of adapalene and dihydrotachysterol as antiviral agents for the Omicron variant of SARS-CoV-2 through computational drug repurposing , 2022, Molecular Diversity.
[9] Elisabeth L. Moussaud-Lamodière,et al. Subcellular mapping of the protein landscape of SARS-CoV-2 infected cells for target-centric drug repurposing , 2022, bioRxiv.
[10] N. Petrovsky,et al. Computational Repurposing of Drugs and Natural Products Against SARS-CoV-2 Main Protease (Mpro) as Potential COVID-19 Therapies , 2022, Frontiers in Molecular Biosciences.
[11] C. Schaffitzel,et al. Synthetic virions reveal fatty acid-coupled adaptive immunogenicity of SARS-CoV-2 spike glycoprotein , 2022, Nature communications.
[12] W. Dawson,et al. Drug repurposing for identification of potential spike inhibitors for SARS-CoV-2 using molecular docking and molecular dynamics simulations , 2022, Methods.
[13] R. Kowsar,et al. The impact of calcitriol and estradiol on the SARS-CoV-2 biological activity: a molecular modeling approach , 2022, Scientific Reports.
[14] A. Salonia,et al. Low testosterone levels predict clinical adverse outcomes in SARS‐CoV‐2 pneumonia patients , 2020, The Journal of Sexual Medicine.
[15] I. Tsigelny,et al. Potential SARS-CoV-2 Spike Protein-ACE2 Interface Inhibitors: Repurposing FDA-approved Drugs , 2022, Journal of Exploratory Research in Pharmacology.
[16] J. Diallo,et al. Antiviral Potential of the Antimicrobial Drug Atovaquone against SARS-CoV-2 and Emerging Variants of Concern , 2021, ACS infectious diseases.
[17] J. McKeating,et al. The circadian clock component BMAL1 regulates SARS-CoV-2 entry and replication in lung epithelial cells , 2021, iScience.
[18] R. Andino,et al. Ethacridine inhibits SARS-CoV-2 by inactivating viral particles , 2021, PLoS pathogens.
[19] S. Mujwar. Computational repurposing of tamibarotene against triple mutant variant of SARS-CoV-2 , 2021, Computers in Biology and Medicine.
[20] Y. Sugita,et al. The inherent flexibility of receptor binding domains in SARS-CoV-2 spike protein , 2021, bioRxiv.
[21] Ankita P. Desai,et al. Vitamin K & D Deficiencies Are Independently Associated With COVID-19 Disease Severity , 2021, Open forum infectious diseases.
[22] Oscar A. Negrete,et al. Discovery of Small-Molecule Inhibitors of SARS-CoV-2 Proteins Using a Computational and Experimental Pipeline , 2021, Frontiers in Molecular Biosciences.
[23] Tudor I. Oprea,et al. A critical overview of computational approaches employed for COVID-19 drug discovery , 2021, Chemical Society reviews.
[24] S. Huo,et al. Recent advances in developing small-molecule inhibitors against SARS-CoV-2 , 2021, Acta Pharmaceutica Sinica B.
[25] N. Petrovsky,et al. In silico comparison of SARS-CoV-2 spike protein-ACE2 binding affinities across species and implications for virus origin , 2021, Scientific Reports.
[26] F. Pelorosso,et al. Telmisartan for treatment of Covid-19 patients: An open multicenter randomized clinical trial , 2021, EClinicalMedicine.
[27] D. Sather,et al. A Repurposed Drug Screen Identifies Compounds That Inhibit the Binding of the COVID-19 Spike Protein to ACE2 , 2021, Frontiers in Pharmacology.
[28] M. Sirota,et al. Transcriptomics-based drug repositioning pipeline identifies therapeutic candidates for COVID-19 , 2021, Scientific Reports.
[29] D. Sahoo,et al. Drug repurposing screens identify chemical entities for the development of COVID-19 interventions , 2021, Nature Communications.
[30] G. Ippolito,et al. Role of testosterone in SARS-CoV-2 infection: A key pathogenic factor and a biomarker for severe pneumonia , 2021, International Journal of Infectious Diseases.
[31] R. Dhar,et al. A large-scale computational screen identifies strong potential inhibitors for disrupting SARS-CoV-2 S-protein and human ACE2 interaction , 2021, Journal of biomolecular structure & dynamics.
[32] Y. Sakurai,et al. iPSC screening for drug repurposing identifies anti‐RNA virus agents modulating host cell susceptibility , 2021, FEBS open bio.
[33] C. Day,et al. Multidisciplinary Approaches Identify Compounds that Bind to Human ACE2 or SARS-CoV-2 Spike Protein as Candidates to Block SARS-CoV-2–ACE2 Receptor Interactions , 2021, mBio.
[34] Jonathan E. Schmitz,et al. Diurnal Variation in SARS-CoV-2 PCR Test Results: Test Accuracy May Vary by Time of Day , 2021, medRxiv.
[35] A. Marcello,et al. Combined in silico and in vitro approaches identified the antipsychotic drug lurasidone and the antiviral drug elbasvir as SARS-CoV2 and HCoV-OC43 inhibitors , 2021, Antiviral Research.
[36] Gengfu Xiao,et al. Drug Repurposing of Itraconazole and Estradiol Benzoate against COVID‐19 by Blocking SARS‐CoV‐2 Spike Protein‐Mediated Membrane Fusion , 2021, Advanced therapeutics.
[37] K. Kadler,et al. Discovery of re-purposed drugs that slow SARS-CoV-2 replication in human cells , 2021, bioRxiv.
[38] M. Leboyer,et al. Chemoinformatic Analysis of Psychotropic and Antihistaminic Drugs in the Light of Experimental Anti-SARS-CoV-2 Activities , 2021, Advances and applications in bioinformatics and chemistry : AABC.
[39] Charlotte K. Colenso,et al. Molecular Simulations suggest Vitamins, Retinoids and Steroids as Ligands of the Free Fatty Acid Pocket of the SARS‐CoV‐2 Spike Protein** , 2021, Angewandte Chemie.
[40] Chi‐Huey Wong,et al. Identification of existing pharmaceuticals and herbal medicines as inhibitors of SARS-CoV-2 infection , 2021, Proceedings of the National Academy of Sciences.
[41] Jue Wang,et al. Screened antipsychotic drugs inhibit SARS-CoV-2 binding with ACE2 in vitro , 2020, Life Sciences.
[42] N. Petrovsky,et al. Computationally repurposed drugs and natural products against RNA dependent RNA polymerase as potential COVID-19 therapies , 2020, Molecular Biomedicine.
[43] G. Pinna. Sex and COVID-19: A Protective Role for Reproductive Steroids , 2020, Trends in Endocrinology & Metabolism.
[44] A. Goc,et al. Polyunsaturated ω-3 fatty acids inhibit ACE2-controlled SARS-CoV-2 binding and cellular entry , 2020, Scientific Reports.
[45] S. Pati,et al. Drug repurposing for identification of potential inhibitors against SARS-CoV-2 spike receptor-binding domain: An in silico approach , 2020, The Indian journal of medical research.
[46] A. Marion,et al. Molecular Modelling Reveals Eight Novel Druggable Binding Sites in SARS-CoV-2’s Spike Protein , 2020 .
[47] Y. Daali,et al. The tyrosine kinase inhibitor nilotinib inhibits SARS‐CoV‐2 in vitro , 2020, Basic & clinical pharmacology & toxicology.
[48] R. Poirier,et al. High-throughput virtual screening of drug databanks for potential inhibitors of SARS-CoV-2 spike glycoprotein , 2020, Journal of biomolecular structure & dynamics.
[49] A. Mulholland,et al. Free fatty acid binding pocket in the locked structure of SARS-CoV-2 spike protein , 2020, Science.
[50] Christopher M. Horvat,et al. Effect of Hydrocortisone on Mortality and Organ Support in Patients With Severe COVID-19: The REMAP-CAP COVID-19 Corticosteroid Domain Randomized Clinical Trial. , 2020, JAMA.
[51] C. Reynolds,et al. Supervised molecular dynamics for exploring the druggability of the SARS-CoV-2 spike protein , 2020, Journal of Computer-Aided Molecular Design.
[52] P. Manickavasagam. Spike Protein of SARS-CoV-2: Impact of Single Amino Acid Mutation and Effect of Drug Binding to the Variant-in Silico Analysis , 2020 .
[53] Krystal L. Matthews,et al. Broad Anti-coronavirus Activity of Food and Drug Administration-Approved Drugs against SARS-CoV-2 In Vitro and SARS-CoV In Vivo , 2020, Journal of Virology.
[54] Yong Wang,et al. Novel and potent inhibitors targeting DHODH are broad-spectrum antivirals against RNA viruses including newly-emerged coronavirus SARS-CoV-2 , 2020, Protein & Cell.
[55] Rafael V. C. Guido,et al. Discovery of clinically approved drugs capable of inhibiting SARS-CoV-2 in vitro infection using a phenotypic screening strategy and network-analysis to predict their potential to treat covid-19 , 2020, bioRxiv.
[56] D. Wang,et al. Calcitriol, the active form of vitamin D, is a promising candidate for COVID-19 prophylaxis , 2020, bioRxiv.
[57] P. Kar,et al. An in-silico study on selected organosulfur compounds as potential drugs for SARS-CoV-2 infection via binding multiple drug targets , 2020, Chemical Physics Letters.
[58] F. Iacovelli,et al. Targeting the SARS-CoV-2 spike glycoprotein prefusion conformation: virtual screening and molecular dynamics simulations applied to the identification of potential fusion inhibitors , 2020, Virus Research.
[59] Lee M. Tatham,et al. Prioritization of Anti‐SARS‐Cov‐2 Drug Repurposing Opportunities Based on Plasma and Target Site Concentrations Derived from their Established Human Pharmacokinetics , 2020, Clinical pharmacology and therapeutics.
[60] A. Santucci,et al. An integrated drug repurposing strategy for the rapid identification of potential SARS-CoV-2 viral inhibitors , 2020, Scientific Reports.
[61] F. Vinckier,et al. [Repurposing of chlorpromazine in COVID-19 treatment: the reCoVery study]. , 2020, L'Encephale.
[62] A. Cachia,et al. Repositionnement de la chlorpromazine dans le traitement du COVID-19 : étude reCoVery , 2020, L'Encéphale.
[63] S. Ciesek,et al. Identification of inhibitors of SARS-CoV-2 in-vitro cellular toxicity in human (Caco-2) cells using a large scale drug repurposing collection , 2020 .
[64] Lee Smith,et al. The role of vitamin D in the prevention of coronavirus disease 2019 infection and mortality , 2020, Aging Clinical and Experimental Research.
[65] Xin Zhou,et al. Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China , 2020, The Journal of Emergency Medicine.
[66] Andreas Koch,et al. Comparison of affinity ranking using AutoDock-GPU and MM-GBSA scores for BACE-1 inhibitors in the D3R Grand Challenge 4 , 2019, Journal of Computer-Aided Molecular Design.
[67] P. Sanseau,et al. Drug repurposing: progress, challenges and recommendations , 2018, Nature Reviews Drug Discovery.
[68] Julie Dyall,et al. Repurposing of Clinically Developed Drugs for Treatment of Middle East Respiratory Syndrome Coronavirus Infection , 2014, Antimicrobial Agents and Chemotherapy.
[69] Tingjun Hou,et al. Assessing the Performance of the MM/PBSA and MM/GBSA Methods. 1. The Accuracy of Binding Free Energy Calculations Based on Molecular Dynamics Simulations , 2011, J. Chem. Inf. Model..
[70] V. Papadopoulos,et al. Caprospinol: moving from a neuroactive steroid to a neurotropic drug , 2009 .
[71] Shibo Jiang,et al. The spike protein of SARS-CoV — a target for vaccine and therapeutic development , 2009, Nature Reviews Microbiology.
[72] V. Papadopoulos,et al. Caprospinol: moving from a neuroactive steroid to a neurotropic drug. , 2009, Expert opinion on investigational drugs.
[73] M. Roden,et al. Thiazolidinediones Influence Plasma Steroids of Male Obese Zucker Rats. , 2002, Endocrinology.